| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6c6755a62b0897623b1be8def62cbee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-201666 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2003-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f2f92f2e8f4053bcee06098ed1c4b8e |
| publicationDate |
2003-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03079026-A1 |
| titleOfInvention |
Method of diagnosing statin myopathy |
| abstract |
The use of statins for the control of hypercholesterolemia is continually increasing. Although the side effects of statins are relatively uncommon, muscle myopathies may develop in response to statin therapy. The invention is the discovery of a correlation between statin related myopathy based on the presence of 3-methylglutaconic acid (3MGA) in the urine. This correlation allows for the screening of both symptomatic and asymptomatic individuals for statin related myopathy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2029771-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103502820-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2029771-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2977764-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012136272-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9664698-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9541565-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013525764-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012136856-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2508895-A1 |
| priorityDate |
2002-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |